Please assess the completion status of the following clinical trial:

Trial Title: A Study of TAK-994 in Adults With Narcolepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Participant with a diagnosis of Narcolepsy Type 1 (NT1) who has completed TAK-994-1501 Part B before enrollment (which will occur immediately following the final TAK-994-1501 assessments), and for whom the investigator has no clinical objection they be enrolled.~Exclusion Criteria:~1. Participant has a clinically significant moderate or severe ongoing AE related to the study drug from the prior study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active Drug Extension Period: TAK-994 30 mg (Type: EXPERIMENTAL): TAK-994 30 mg, twice daily (BID) tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Active Drug Extension Period: TAK-994 90 mg (Type: EXPERIMENTAL): TAK-994 90 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Active Drug Extension Period: TAK-994 180 mg (Type: EXPERIMENTAL): TAK-994 180 mg, BID, tablets, orally, from Day 1 (Day 57 of previous study) to Day 56 in the Active Drug Extension Period.
- Double-blind Randomized Withdrawal Period: TAK-994 30 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 30 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 30 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: TAK-994 90 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 90 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 90 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: TAK-994 180 mg (Type: EXPERIMENTAL): Following the Active Drug Extension Period, participants randomized to active treatment 180 mg, BID, meeting eligibility specification and continued to receive same dose (TAK-994, 180 mg, BID, tablets, orally) from Day 57 to Day 84 in the Double-blind Randomized Withdrawal Period.
- Double-blind Randomized Withdrawal Period: Placebo (Type: PLACEBO_COMPARATOR): Following the Active Drug Extension Period participants meeting eligibility specification and received placebo-matching tablets for 4 weeks (from Day 57 to Day 84) in the Double-blind Randomized Withdrawal Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).